Viromed Medical AG has received funding approval from Germany's Federal Ministry of Research, Technology and Space for research and development projects in cold plasma technology. The certification was granted under the Research Allowance Act (FZulG) and comprises funding in the high six-figure euro range, marking a substantial investment in medical innovation. This financial support enables Viromed to advance development of specialized medical systems that could transform treatment approaches for infectious diseases without relying on traditional pharmaceuticals.
The funding focuses on developing innovative medical systems for cold atmospheric plasma application, including a stationary system for integration into ventilation processes called PulmoPlas®. This technology aims to selectively inactivate pathogenic germs in the lower respiratory tract, potentially enabling new therapeutic approaches in intensive care medicine. The application of cold plasma in the lungs represents a particularly novel approach for which no comparable systems currently exist, according to the company. This development addresses critical challenges in treating respiratory infections, especially in intensive care settings where conventional treatments may have limitations.
Additionally, the development of a mobile device for contact-free plasma application to support wound healing, known as ViroCap®, is being funded through this initiative. Both projects address key medical challenges and expand the current state of the art in medical technology. The funding underscores Viromed's innovative capabilities and confirms the scientific and technological relevance of its solutions in the medical field. With this financial support, Viromed is advancing the development of both PulmoPlas® and ViroCap® systems, strengthening its position in non-pharmacological treatment of infectious diseases.
The company, which has been listed on the stock exchange since October 2022, focuses on distributing innovative cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. More information about the company can be found at https://www.viromed-medical-ag.de. The funding represents a significant step toward realizing the growth potential of cold plasma technology in medicine. By developing these specialized systems, Viromed aims to provide healthcare professionals with new tools to combat infections and improve patient outcomes through advanced technological solutions that operate without traditional pharmaceuticals. This development could potentially reduce reliance on antibiotics and other pharmaceutical interventions, addressing growing concerns about antimicrobial resistance while offering alternative treatment modalities for complex medical conditions.
